close

Columbia Laboratories, Inc. engages in the research, development, and commercialization of women's healthcare and endocrinology products. Its products are used to treat infertility, endometriosis, dysmenorrhea, preterm birth for women with a short cervix at mid-pregnancy, and hormonal deficiencies. The company's products primarily utilize its patented Bioadhesive Delivery System technology. The company markets vaginal progesterone gel products to assist women who are infertile become pregnant in the United States, which include CRINONE 8% for technical procedures to reproductive endocrinologists; PROCHIEVE 8% to obstetricians and gynecologists; and PROCHIEVE 4% for treatment of secondary amenorrhea. It also provides vaginal gel women's products, such as Replens, a vaginal moisturizer for replenishment of vaginal moisture; RepHresh vaginal gel that eliminates vaginal odor; and Advantage-S, a female contraceptive gel. In addition, the company offers STRIANT, a testosterone buccal system for the treatment of hypogonadism in men; and Advance Formula Legatrin PM for the relief of occasional pain and sleeplessness associated with minor muscle aches. Further, it engages in clinical development activities of vaginally-administered lidocaine to prevent and treat dysmenorrhea, as well as vaginally-administered carbamide peroxide for treating vaginal infections; and testosterone progressive hydration vaginal tablet for women, which completed phase I trial. The company was founded in 1986 and is based in Livingston, New Jersey.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	0.68
Volume	(mio) 1.1
Volume Avg	(mio) 2.15
52 Week High	4.31
52 Week Low	0.62
PE	3.20
PE (group average)	39
EPS Year	0.22
EPS change Q/Q	-83.33%
EPS change Q/Q Yr ago	-95%
EPS change Q/Q next Q est	1000%
EPS change Y/Y	-284.62%
REV change Q/Q	-16.11%
REV change Q/Q Yr ago	73.61%
EPS next Q est	0.01
EPS next Y est	0.11
Divident Annual	0.00
Dividend Yield	0%